Product Description: Pepstatin (Pepstatin A) is a specific, orally active aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin also inhibits HIV protease[1][2].
Applications: COVID-19-anti-virus
Formula: C34H63N5O9
Citations: ACS Nano. 2024 Jun 13./Adv Sci (Weinh). 2022 Oct 10;e2203831./Adv Sci (Weinh). 2023 Oct;10(28):e2302130./Arch Biochem Biophys. 2023 May 22, 109646./Biochem Bioph Res Co. 2020 Sep 10;530(1):292-300./Biochem Biophys Res Commun. 2024 Jun 15:725:150271./bioRxiv. 2023 Nov 5./Cancer Lett. 2022 Mar 9;215629./Carbohydr Polym. 2023 Jul 17, 121208./Cell Death Dis. 2022 Dec 16;13(12):1048./Cell Rep. 2021 Nov 2;37(5):109931./Environ Sci Technol. 2017 Dec 5;51(23):13938-13948./Eur J Pharmacol. 2022 Feb 11;920:174823./FASEB J. 2022 Jan;36(1):e22121./Int J Oncol. 2019 Jul;55(1):331-339./J Virol. 2021 Sep 22;JVI0153721./J Virol. 2023 Oct 17:e0107523./Mol Med Rep. 2019 Jan;19(1):41-50./Mol Pharm. 2024 May 9./Pharmaceuticals. 2022, 15(12), 1509/Pharmacol Res. 2021 Dec 1;175:105985./PLoS Pathog. 2024 Feb 14;20(2):e1011981./Redox Biol. 2024 Apr:70:103064./Sci Adv. 2022 Nov 11;8(45):eabn6579./SSRN. 2023 Apr 10./Toxicol Appl Pharmacol. 2018 Oct 1;356:159-171. /ACS Nano. 2024 Jan 10./Int J Antimicrob Agents. 2019 Dec;54(6):814-819./Biol Pharm Bull. 2022 Feb 3.
References: [1]Umezawa H, et al. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J Antibiot (Tokyo). 1970 May;23(5):259-62./[2]Seelmeier S, et al. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6612-6.
CAS Number: 26305-03-3
Molecular Weight: 685.89
Compound Purity: 98.59
Research Area: Infection; Inflammation/Immunology
Solubility: DMSO : 31.25 mg/mL (ultrasonic)
Target: Autophagy;HIV Protease
English
Deutsch
